CoChat

Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

Open access
Matsumura, Y, Hamaguchi, T, Ura, T, Muro, K, Yamada, Y, Shimada, Y, Shirao, K, Okusaka, T, Ueno, H, Ikeda, M, Watanabe, N · 2004 · British Journal of Cancer

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and is one of the successful polymer micelle systems to exhibit an efficient accumulation in solid tumours in mice. The purpose of this study was to define the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of NK911 and to evaluate its pharmacokinetic profile in man. NK911 was given intravenously to patients with solid tumours every 3 weeks using an infusion pump at a rate of 10 mg DXR equivalent min(-1). The starting dose was 6 mg DXR equivalent m(-2), and the dose was escalated according to the accelerated titration method. A total of 23 patients participated in this study. Neutropenia was the predominant haematological toxicity, and grade 3 or 4 neutropenia was observed at doses of 50 and 67 mg m(-2). Common nonhaematological toxicities were mild alopecia, stomatitis, and anorexia. In the dose identification part of the study, DLTs were observed at a dose of 67 mg m(-2) (grade 4 neutropenia lasting more than 5 days). Thus, this dosage level was determined to be the MTD. Infusion-related reactions were not observed in any cases. The C(5 min) and area under the concentration curve parameters of NK911 exhibited dose-dependent characteristics. Among the 23 patients, a partial response was obtained in one patient with metastatic pancreatic cancer. NK911 was well tolerated and produced only moderate nausea and vomiting at myelosuppressive dosages. The recommended phase II dose was determined to be 50 mg m(-2) every 3 weeks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6602204

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic structure of NK911. A polymeric micelle carrier of NK911 consists of a block copolymer of PEG (molecular weight of about 5000) and poly(aspartic acid) (about 30 units). Polyethyleneglycol is believed to be the outer shell of the micelle. NK911 has a highly hydrophobic inner core, and therefore can entrap sufficient amounts of DXR.
Figure 1 Schematic structure of NK911. A polymeric micelle carrier of NK911 consists of a block copolymer of PEG (molecular weight of about 5000) and poly(aspartic acid) (about 30 units). Polyethyleneglycol is believed to be the outer shell of the micelle. NK911 has a highly hydrophobic inner core, and therefore can entrap sufficient amounts of DXR.CC BY · PubMed Central
Figure 2 Mean plasma levels of doxorubicin following the intravenous administration of NK911 at dosages of 6, 12, 24, 36, 50, and 67 mg m−2 in 23 patients.
Figure 2 Mean plasma levels of doxorubicin following the intravenous administration of NK911 at dosages of 6, 12, 24, 36, 50, and 67 mg m−2 in 23 patients.CC BY · PubMed Central
Figure 3 Correlations between dosage and AUC0–inf (A) and C5 min (B) after a single intravenous administration of NK911.
Figure 3 Correlations between dosage and AUC0–inf (A) and C5 min (B) after a single intravenous administration of NK911.CC BY · PubMed Central
Figure 4 Serial CT scans of a 69-year-old male with pancreatic cancer who was treated with NK911 at an initial dosage level of 67 mg m−2 during the first course and at 50 mg m−2 after the second course. Changes in tumour marker levels are also shown. (A) Baseline scan showing a metastasis in the left lateral lobe. (B) Partial response, characterised by a more than 50% decrease in the size of the liver metastasis compared with the baseline scan. (C) Tumour markers, CA19-9 and CEA, decreased remarkably after treatment.
Figure 4 Serial CT scans of a 69-year-old male with pancreatic cancer who was treated with NK911 at an initial dosage level of 67 mg m−2 during the first course and at 50 mg m−2 after the second course. Changes in tumour marker levels are also shown. (A) Baseline scan showing a metastasis in the left lateral lobe. (B) Partial response, characterised by a more than 50% decrease in the size of the liver metastasis compared with the baseline scan. (C) Tumour markers, CA19-9 and CEA, decreased remarkably after treatment.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 623

Metadata

Authors
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., & Watanabe, N.
Affiliations
  • National Cancer Center Hospital East (JP)
  • National Cancer Center Hospital (JP)
  • Nippon Kayaku (Japan) (JP)
Corresponding author
Matsumura, Y
Venue
British Journal of Cancer
Published
2004-10-12
Volume
91
Issue
10
Pages
1775-1781
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2056347214
Cited by
623
References
17
Citations by year
2026: 10 · 2025: 11 · 2024: 20 · 2023: 18 · 2022: 28 · 2021: 35 · 2020: 28 · 2019: 23 · 2018: 25 · 2017: 37 · 2016: 42 · 2015: 38 · 2014: 53 · 2013: 28 · 2012: 54
FWCI
8.54
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords
doxorubicin, polymeric micelles, supramolecular nanocarriers, maximum tolerated dose, dose-limiting toxicity, neutropenia, pharmacokinetics, solid tumors, metastatic pancreatic cancer, accelerated titration, recommended phase 2 dose, drug delivery
MeSH terms
Aged, Antineoplastic Agents, Doxorubicin, Drug Administration Schedule, Female, Humans, Male, Micelles, Middle Aged, Nausea, Neoplasms, Neutropenia, Peptides, Polyethylene Glycols, Vomiting, Maximum Tolerated Dose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. https://app.cochat.ai/papers/10.1038/sj.bjc.6602204
The paper
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., & Watanabe, N. (2004). Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6602204

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.